Buradasınız

Anasayfa » Content

Yüzeyel Mesane Tümörlerinin Tedavisinde İntravezikal BCG Uygulamasının Sonuçlar

The Results Of Intravesical Bcg Therapy in The Management of Superficial Bladder Tumors

Journal Name:

  • Uludağ Üniversitesi Tıp Fakültesi Dergisi

Publication Year:

  • 2005

Key Words:

Keywords (Original Language):

Author NameUniversity of Author
Abstract (2. Language): 
In this study, we aimed to evaluate the efficacy of Bacillus Calmette-Guerin (BCG) therapy administered intravesically in patients with superficial bladder tumors carrying moderate to high risk of recurrence. Fifty five patients undergoing transurethral resection of bladder tumors (TUR-BT) for the treatment of superficial transitional cell bladder tumor between 1992 and 2003 were included in the study. Three weeks after the resection, the patients received 81 mg of Pasteur BCG intravesically once a week for 6 weeks. In 27 of the patients, this therapy was continued as once a month for 6 months following the 6 weeks treatment period. TUR-BT was performed in patients who were determined to have recurrence of the tumor and, grade, stage and progression of the tumor and the time period of the recurrences were recorded. Recurrences were observed in 15 (27%) of 55 patients who have been followed up for 36.42±3.16 months in average (12- 126 months). In 2 (13%) of 15 patients having recurrences, there was an increase in the grade as well as stage of the tumor histopathologically. Intravesical BCG immunotherapy applied after TUR-BT is an effective therapeutic option to prevent recurrence and progression of the superficial bladder tumors carrying moderate and high risk of recurrence.
Bookmark/Search this post with
Abstract (Original Language): 
Bu çalışmada, orta ve yüksek nüks riski taşıyan yüzeyel mesane tümörlü olgulara uygulanan intravezikal Bacillus Calmette-Guerin (BCG) tedavisinin etkinliğinin değerlendirilmesi amaçlandı. 1992-2003 tarihleri arasında değişici epitel hücreli yüzeyel mesane tümörlü olgulara transüretral rezeksiyon-mesane tümörü (TUR-MT) uygulandı. TUR-MT’den 3 hafta sonra 55 olgunun 28 tanesine 6 hafta süreyle haftada 1 kez intravezikal 81 mg Pasteur BCG verilirken, 27’sine 6 haftalık tedaviyi takiben ayda 1 kez olmak üzere toplam 6 aylık tedavi uygulandı. Nüks saptanan olgulara TUR-MT yapılıp tümörün grade’i, evresi, progresyonu ve nüks süresi kaydedildi. Ortalama 36.42±3.16 ay (12-126 ay) süreyle takip edilen 55 hastadan 15’inde (% 27) nüks gözlenmiştir. Nüks gözlenen 15 hastadan 2’sinde (% 13) histopatolojik olarak tümörün grade ve evresinde artış izlenmiştir. Orta ve yüksek nüks riski taşıyan yüzeyel mesane tümörlerinde, TUR-MT sonrası intravezikal BCG immünoterapisi tümör nüks ve progresyonunu önlemede oldukça etkili bir tedavi seçeneğidir.
FULL TEXT (PDF): 
PDF icon arastirmax-yuzeyel-mesane-tumorlerinin-tedavisinde-intravezikal-bcg-uygulamasinin-sonuclar.pdf
  • 1
31-34
  • Turkish

REFERENCES

References: 

1. Vicente J, Chechile G, Pons R, Mendez G: Tumor recurrence
in prostatic urethra following simultaneous resection of
bladder tumor and prostate. Eur Urol 1988; 15(1-2):40-2.
2. Lutzeyer W, Rubben H, Dahm H. Prognostic parameters in
superficial bladder cancer: an analysis of 315 cases. J Urol
1982; 127(2):250-2.
3. Golomb J, Gorelik U, Keler T, Lindner A: Incidence and
pattern of bladder tumor recurrence following combined
suprapubic prostatectomy and excision of a bladder tumor.
Eur Urol. 1989;16(2):86-8.
4. Kurth KH, Denis L, Bouffioxs C, et al: Factors affecting
recurrence and progression in superficial bladder tumors. Eur
J Cancer 1995; 31A(11): 1840-6.
5. Witjes JA, Kiemenig La LM, Oosterhof GON, et al:
Prognostic factors in superficial bladder cancer. Eur Urol
1992; 21:89-97.
6. Miladi M, Peyramaura M, Zerbib M, Saighi D, Debre B: The
value of a second transurethral resection in evaluating patients
with bladder tumours. Eur Urol 2003; 43: 241-5.
7. Kamat AM, Lamm DL: Intravesical therapy for bladder
cancer. Urology 2000;55: 161-8.
8. Herr HW, Laudone VP, Whitmore WF, Jr.: An overview of
intravesical therapy of superficial bladder tumors. J Urol
1987; 138(6):1363-8.
9. Herr HW, Dalbagni G: Defining bacillus Calmette-Guerin
refractory superficial bladder tumors. J Urol 2003;
169(5):1706-8.
10. Tsivian A, Shtricker A, Sıdı AA: Simultaneous transurethral
resection of bladder tumor and benign prostatic hyperplasia:
Hazardous or a safe timesaver? J Urol 2003; 170(6 Pt 1):2241-
3.
11. Pode D, Alon Y, Horowitz AT, Vlodansky I, Biran S: The
mechanism of human bladder tumor implantation in an in
vitro model. J Urol 1986; 136(2):482-6.
12. Lamm DL, Griffith JG. Intravesical therapy: does it affect the
natural history of superficial bladder cancer? Semin Urol
1992; 10(1):39-44.
13. Brosman SA: BCG immunotherapy technique and results.
Urol Clin North Am. 1992 Aug;19(3):557-64.
14. Herr HW, Pinsky CM, Whitmore WF, et al: Experience with
bacillus Calmette-Guerin therapy of superficial bladder
tumors. Urology. 1985 Feb;25(2):119-23.
15. Morales A, Eidinger D, Bruce AW. Intracavitary BCG in the
treatment of superficial bladder tumors. J Urol 1976;
116(2):180-3
16. Kavoussi LR, Torrence RJ, Gillen DP, et al. Results of 6
weekly intravesical bacillus Calmette-Guerin instillations on
the treatment of superficial bladder tumors. J Urol. 1988
May;139(5):935-40
17. Lamm DL, Thor DE, Haris EC, et al: Bacillus CalmetteGuerin immunotherapy for s bladder cancer. J Urol 1980;
124(1):38-40.
18. Kolodzıej A, Dembowski J, Zdrojowy R, Wozniak P, Lorenz
J: Treatment of high-risk superficial bladder cancer with
maintenanace bacillus Calmette-Guerin therapy: preliminary
results. BJU Int 2002; 89: 620-2.
19. Sylvester RJ, van der Meıjden AP, Lamm DL: Intravesical
bacillus Calmette-Guerin reduces the risk of progression in
patients with superficial bladder cancer: a meta-analysis of the
published results of randomized clinical trials. J Urol. 2002
Nov;168(5):1964-70.
20. Krege S, Giani G, Meyer R, Otto T, Rubben H. A randomized
multicenter trial of adjuvant therapy in superficial bladder
cancer: transurethral resection only versus transurethral
resection plus mitomycin C versus transurethral resection plus
bacillus Calmette-Guerin. Participating Clinics. J Urol. 1996
Sep;156(3):962-6.
21. Melekos MD, Chionis H, Pantazakos A, Fokaefs E,
Paranychianakis G, Dauaher H. Intravesical bacillus CalmetteGuerin immunoprophylaxis of superficial bladder cancer:
results of a controlled prospective trial with modified
treatment schedule. J Urol. 1993 Apr;149(4):744-8.
22. Badalament RA, Herr HW, Wong GY, et al. A prospective
randomized trial of maintenance versus nonmaintenance
intravesical BCG therapy of superficial bladder cancer. J Clin
Oncol. 1987; 5(3):441-9.

Thank you for copying data from http://www.arastirmax.com